Microscopic colitis-microbiome, barrier function and associated diseases.
| Autor: | van Hemert S; Winclove Probiotics, Amsterdam, the Netherlands., Skonieczna-Żydecka K; Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Szczecin, Poland., Loniewski I; Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Szczecin, Poland.; Sanprobi Sp. z o.o. Sp. K., Szczecin, Poland., Szredzki P; Endoscopy Unit, Department of Surgery, Hospital Sędziszów Małopolski, Sędziszów Małopolski, Poland., Marlicz W; Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of translational medicine [Ann Transl Med] 2018 Feb; Vol. 6 (3), pp. 39. |
| DOI: | 10.21037/atm.2017.03.83 |
| Abstrakt: | Microscopic colitis (MC) is a chronic inflammatory bowel disease (IBD) with little in terms of endoscopic abnormalities and is frequently associated with other autoimmune diseases. The peak incidence of the disease is in middle aged or older populations, mostly females. The pathogenesis of MC is complex, multifactorial and poorly understood. Current concepts revolve around innate immunity or microbiome alterations as well as gut barrier dysfunction, all of which lead to the development of subtle inflammatory lesions in gut mucosa. The results of numerous basic and clinical studies involving molecular techniques as well as advanced endoscopic imaging revealed the important role of both intrinsic (e.g., hormonal) as well as extrinsic (e.g., NSAIDs and PPIs) factors in the modulation of gastrointestinal microbiome and MC pathogenesis. Capsule endoscopy as well confocal endomicroscopy imaging, alongside standard endoscopic techniques offer new tools in the evaluation of MC patients and allow their better stratification for novel treatment protocols based on modulation of gut microbiome and barrier function. Competing Interests: Conflicts of Interest: S van Hemert is employee in Winclove (Winclove manufactures and markets probiotics). I Loniewski and W Marlicz are shareholders in Sanprobi (Sanprobi is a probiotic producing and marketing company). The content of this study was neither influenced nor constrained by these facts. The other authors have no conflicts of interest to declare. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|